Supplements

Digital cognitive behavioral therapy for insomnia (dCBT-I) improves sleep onset latency in chronic insomnia patients, with effects comparable to zolpidem at 5 weeks and sustained at 10 weeks.

In a small exploratory RCT, a 5-week dCBT-I app reduced subjective sleep onset latency (sSOL) by -20.65 min at Week 5, similar to zolpidem (-22.42 min, p=0.7729). At Week 10 follow-up, dCBT-I showed sustained improvement (-29.02 min) while zolpidem showed slight recurrence (-16.19 min). No treatment-related adverse events occurred in the dCBT-I group.

Last updated: Aug 26, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial.

observational

Shimizu E, Sato D, Miyoshi M, Ebisu H, Takahashi K, Inaba Y, Inoue Y, Osao M, Takeshima M, Ogasawara M, Hirano Y, Hanaoka H · Sleep medicine (2026)

Participants: N/A
Duration: 10 weeks (5-week treatment + 5-week follow-up)
Intervention: 5-week fully unguided digital cognitive behavioral therapy for insomnia (dCBT-I) application 'IIIP MED: Sleepy Med'
Outcome: Subjective Sleep Onset Latency (sSOL) change from baseline at Week 5 and Week 10; secondary outcomes included objective sleep parameters via portable EEG and safety assessments
Effect Size: N/A (between-group difference p=0.7729 at Week 5)
Population: Patients with chronic sleep-onset insomnia who remained symptomatic after 4-week screening following sleep hygiene education (N=24)

Result:

PubMed: 42623797DOI: 10.1016/j.sleep.2026.109222

Mechanism Graph

dCBT-I targets dysfunctional beliefs and attitudes about sleep
↓
Provides structured behavioral interventions (e.g., stimulus control, sleep restriction) via app
↓
Improves sleep onset latency over 5 weeks
↓
Effects maintained at 10-week follow-up, with greater improvement in dysfunctional beliefs

Limitations

  • ⚠Small sample size (N=24) leading to underpowered study
  • ⚠Exploratory design, not confirmatory
  • ⚠High dropout rate (dCBT-I group n=9 at Week 10, zolpidem n=12)
  • ⚠No blinding for the dCBT-I group (likely unblinded)

Frequently Asked Questions

How does dCBT-I compare to zolpidem for insomnia?▼

At 5 weeks, both dCBT-I and zolpidem significantly reduced sleep onset latency with no significant difference between groups. However, at 10-week follow-up, dCBT-I maintained improvement while zolpidem showed slight recurrence.

Is dCBT-I safe?▼

No treatment-related adverse events were reported in the dCBT-I group, while one case of daytime somnolence occurred in the zolpidem group.

What is the duration of the dCBT-I treatment?▼

The dCBT-I treatment lasted 5 weeks, with a 5-week post-treatment follow-up.

What is the primary outcome measured in this study?▼

The primary outcome was the change in subjective Sleep Onset Latency (sSOL) from baseline at Week 5.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Shimizu E, Sato D, Miyoshi M, Ebisu H, Takahashi K, Inaba Y, Inoue Y, Osao M, Takeshima M, Ogasawara M, Hirano Y, Hanaoka H. "Efficacy and safety of a novel digital cognitive behavioral therapy for insomnia application versus zolpidem: An exploratory randomized controlled trial.." Sleep medicine, 2026. PMID: 42623797 DOI: 10.1016/j.sleep.2026.109222
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.